NMR Characterization of the Interaction of the Endonuclease Domain of MutL with Divalent Metal Ions and ATP

Mizushima R, Kim JY, Suetake I, Tanaka H, Takai T, et al. (2014) NMR Characterization of the Interaction of the Endonuclease Domain of MutL withDivalent Metal Ions and ATP. PLoS ONE 9(6): e98554. doi:10.1371/journal.pone.009855

NMR Characterization of the Interaction of the Endonuclease Domain of MutL with Divalent Metal Ions and ATP

Mizushima R, Kim JY, Suetake I, Tanaka H, Takai T, et al. (2014) NMR Characterization of the Interaction of the Endonuclease Domain of MutL withDivalent Metal Ions and ATP. PLoS ONE 9(6): e98554. doi:10.1371/journal.pone.009855

Biochemistry and Molecular Biology Effect of Nerve Growth Factor on the In Vitro Induction of Apoptosis of Human Conjunctival Epithelial Cells by Hyperosmolar Stress

Citation: Kang S-S, Ha S-J, Kim E-S, Shin J-A, Kim JY, Tchah H. Effect of nerve growth factor on the in vitro induction of apoptosis of human conjunctival epithelial cells by hyperosmolar stress. Invest Ophthalmol Vis Sci. 2014;55:535-541

Optical and Near-Infrared Imaging of the IRAS 1-Jy Sample of Ultraluminous Infrared Galaxies: I. The Atlas

An imaging survey of the {\em IRAS} 1-Jy sample of 118 ultraluminous infrared galaxies was conducted at optical (R) and near-infrared (K') wavelengths using the University of Hawaii 2.2m telescope. The methods of observation and data reduction are described. An R and K' atlas of the entire sample is presented along with some of the basic astrometric and photometric parameters derived from these images. A more detailed analysis of these data is presented in a companion paper (Veilleux, Kim, & Sanders 2002; astro-ph/0207401).Comment: Correction to D.-C. Kim's affiliations. 10 pages + 3 tables + a 24-page jpg atlas; see http://www.astro.umd.edu/~veilleux/pubs/paper1.tar.gz for original figure

Genotyping of single nucleotide polymorphisms related to attention-deficit hyperactivity disorder

Pharmacological treatment of several diseases, such as attention-deficit hyperactivity disorder (ADHD), presents marked variability in efficiency and its adverse effects. The genotyping of specific single nucleotide polymorphisms (SNPs) can support the prediction of responses to drugs and the genetic risk of presenting comorbidities associated with ADHD. This study presents two rapid and affordable microarray-based strategies to discriminate three clinically important SNPs in genes ADRA2A, SL6CA2, and OPRM1 (rs1800544, rs5569, and rs1799971, respectively). These approaches are allele-specific oligonucleotide hybridization (ASO) and a combination of allele-specific amplification (ASA) and solid-phase hybridization. Buccal swab and blood samples taken from ADHD patients and controls were analyzed by ASO, ASA, and a gold-reference method. The results indicated that ASA is superior in genotyping capability and analytical performance.This research has been funded through projects FEDER MINECO INNPACTO IPT-2011-1132-010000, CTQ/2013/45875R, and PrometeoII/2014/040 (GVA).Tortajada-Genaro, LA.; Mena-Mollá, S.; Niñoles Rodenes, R.; Puigmule, M.; Viladevall, L.; Maquieira Catala, Á. (2016). Genotyping of single nucleotide polymorphisms related to attention-deficit hyperactivity disorder. Analytical and Bioanalytical Chemistry. 408(9):2339-2345. https://doi.org/10.1007/s00216-016-9332-3S233923454089Cortese S. The neurobiology and genetics of Attention-Deficit/Hyperactivity Disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol. 2012;16:422–33.Contini V, Rovaris DL, Victor MM, Grevet EH, Rohde LA, Bau CH. Pharmacogenetics of response to methylphenidate in adult patients with attention-deficit/hyperactivity disorder (ADHD): a systematic review. Eur Neuropsychopharmacol. 2013;23:555–60.Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3):521–90.Abul-Husn NS, Obeng AO, Sanderson SC, Gottesman O, Scott SA. Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics Pers Med. 2014;7:227.Altman RB, Flockhart D, Goldstein DB, editors. Principles of pharmacogenetics and pharmacogenomics. Cambridge: Cambridge University Press; 2012.Hawi Z, Cummins TDR, Tong J, Johnson B, Lau R, Samarrai W, et al. The molecular genetic architecture of attention deficit hyperactivity disorder. Mol Psychiatry. 2015;20:289–97.Limaye N. Pharmacogenomics, Theranostics and Personalized Medicine-the complexities of clinical trials: challenges in the developing world. Appl Transl Genomics. 2013;2:17–21.Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med. 2013;15:258–67.Kim S, Misra A. PharmGKB: the Pharmacogenomics Knowledge Base. Annu Rev Biomed Eng. 2007;9:289–320.Lucarelli F, Tombelli S, Minunni M, Marrazza G, Mascini M. Electrochemical and piezoelectric DNA biosensors for hybridisation detection. Anal Chim Acta. 2008;609:139–59.Knez K, Spasic D, Janssen KP, Lammertyn J. Emerging technologies for hybridization based single nucleotide polymorphism detection. Analyst. 2014;139:353–70.Choi JY, Kim YT, Byun JY, Ahn J, Chung S, Gweon DG, et al. Integrated allele-specific polymerase chain reaction–capillary electrophoresis microdevice for single nucleotide polymorphism genotyping. Lab Chip. 2012;12:5146–54.Ragoussis J. Genotyping Technologies for Genetic Research. Annu Rev Genomics Hum Genet. 2009;10:117–33.Sethi D, Gandhi RP, Kuma P, Gupta KC. Chemical strategies for immobilization of oligonucleotides. Biotechnol J. 2009;4:1513–29.Bañuls MJ, Morais SB, Tortajada-Genaro LA, Maquieira A. Microarray Developed on Plastic Substrates. Microarray Technology: Methods and Applications, 2016; 37-51.Tortajada-Genaro LA, Rodrigo A, Hevia E, Mena S, Niñoles R, Maquieira A. Microarray on digital versatile disc for identification and genotyping of Salmonella and Campylobacter in meat products. Anal Bioanal Chem. 2015;407:7285–94.Kieling C, Genro JP, Hutz MH, Rohde LA. A current update on ADHD pharmacogenomics. Pharmacogenomics. 2010;11:407–19.Kim BN, Kim JW, Cummins TD, Bellgrove MA, Hawi Z, Hong SB, et al. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder. J Clin Psychopharmacol. 2013;33:356–62.Carpentier PJ, Arias Vasquez A, Hoogman M, Onnink M, Kan CC, Kooij JJS, et al. Shared and unique genetic contributions to attention deficit/hyperactivity disorder and substance use disorders: A pilot study of six candidate genes. Eur Neuropsychopharmacol. 2013;23:448–57.Zhang Y, Haraksingh R, Grubert F, Abyzov A, Gerstein M, Weissman S, et al. Child development and structural variation in the human genome. Child Dev. 2013;84:34–48.Asari M, Watanabe S, Matsubara K, Shiono H, Shimizu K. Single nucleotide polymorphism genotyping by mini-primer allele-specific amplification with universal reporter primers for identification of degraded DNA. Anal Biochem. 2009;386:85–90.Choi JY, Kim YT, Ahn J, Kim KS, Gweon DG, Seo TS. Integrated allele-specific polymerase chain reaction–capillary electrophoresis microdevice for single nucleotide polymorphism genotyping. Biosens Bioelectron. 2012;35:327–34.Konstantou JK, Ioannou PC, Christopoulos TK. Dual-allele dipstick assay for genotyping single nucleotide polymorphisms by primer extension reaction. Eur J Hum Genet. 2009;17:105–11.Sebastian T, Cooney CG, Parker J, Qu P, Perov A, Golova JB, et al. Integrated amplification microarray system in a lateral flow cell for warfarin genotyping from saliva. Clin Chim Acta. 2014;429:198–205

Optical Spectroscopy of the IRAS 1-Jy Sample of Ultraluminous Infrared Galaxies

This paper discusses the optical spectroscopic properties of the IRAS 1-Jy sample of ultraluminous infrared galaxies (ULIGs). One hundred and eight of the 118 1-Jy ULIGs have been observed at dlambda = 8.3 AA resolution over the wavelength range ~4500 A -- 8900 A. These data are combined with large, previously published sets of optical spectroscopic data of lower luminosity infrared galaxies to look for systematic trends with infrared luminosity over the luminosity range L_ir ~ 10^{10.5}-10^{13} L_sun. As found in previous studies, the fraction of Seyfert galaxies among luminous infrared galaxies increases abruptly above L_ir ~ 10^{12.3} L_sun --- about 50% of the galaxies with L_ir > 10^{12.3} L_sun present Seyfert characteristics. Many of the optical and infrared spectroscopic properties of the Seyfert galaxies are consistent with the presence of a genuine active galactic nucleus (AGN). About 30% of these galaxies are Seyfert 1s with broad-line regions similar to those of optical quasars. The percentage of Seyfert 1 ULIGs increases with infrared luminosity, contrary to the predictions of the standard unification model for Seyfert galaxies. Comparisons of the broad-line luminosities of optical and obscured Seyfert 1 ULIGs with those of optically selected quasars of comparable bolometric luminosity suggest that the dominant energy source in most of these ULIGs is the same as in optical quasars, namely mass accretion onto a supermassive black hole, rather than a starburst. These results are consistent with recently published ISO, ASCA, and VLBI data. (abridged)Comment: Text and 23 figures (45 pages), Tables 1 - 6 (16 pages

The Role of Starburst-AGN composites in Luminous Infrared Galaxy Mergers: Insights from the New Optical Classification Scheme

We investigate the fraction of starbursts, starburst-AGN composites, Seyferts, and LINERs as a function of infrared luminosity (L_IR) and merger progress for ~500 infrared-selected galaxies. Using the new optical classifications afforded by the extremely large data set of the Sloan Digital Sky Survey, we find that the fraction of LINERs in IR-selected samples is rare (< 5%) compared with other spectral types. The lack of strong infrared emission in LINERs is consistent with recent optical studies suggesting that LINERs contain AGN with lower accretion rates than in Seyfert galaxies. Most previously classified infrared-luminous LINERs are classified as starburst-AGN composite galaxies in the new scheme. Starburst-AGN composites appear to "bridge" the spectral evolution from starburst to AGN in ULIRGs. The relative strength of the AGN versus starburst activity shows a significant increase at high infrared luminosity. In ULIRGs (L_IR >10^12 L_odot), starburst-AGN composite galaxies dominate at early--intermediate stages of the merger, and AGN galaxies dominate during the final merger stages. Our results are consistent with models for IR-luminous galaxies where mergers of gas-rich spirals fuel both starburst and AGN, and where the AGN becomes increasingly dominant during the final merger stages of the most luminous infrared objects.Comment: 30 pages, 19 figures, 10 tables, ApJ accepte